Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071723 | 0.89 | ALDH1A1 (0.47) | SMN1; SMN2GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL926321 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAEGLN1VNN1 | |
| SCHEMBL10289328 | 0.85 | PPARA (0.55) | SMN1; SMN2GAAALDH1A1KMT2AMEN1 | |
| SCHEMBL1482556 | 0.85 | ALDH1A1 (0.50) | GAAALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16661979 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAGPR34LMNAVNN1 | |
| Hydrochloric Acid SCHEMBL926320 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAEGLN1VNN1 | |
| SCHEMBL4841724 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAEGLN1 | |
| SCHEMBL4076916 | 0.84 | LMNA (0.62) | GAAALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4932550 | 0.83 | MMP3 (0.47) | SMN1; SMN2GAAEGLN1 | |
| SCHEMBL3190220 | 0.83 | ALOX15 (0.61) | SMN1; SMN2GAAGPR34EGLN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | SMN1; SMN2 2595/4885GAA 1612/4885ALDH1A1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.